About Elektrofi
Elektrofi is a Healthcare company based in Boston (United States) founded in 2016 by Chase Coffman and Jason Norris, and was acquired by Halozyme in October 2025. Digital platform transforming the delivery of biologic medicines. Elektrofi has raised $152.25 million across 4 funding rounds from investors including Lilly, Halozyme and Royalty Pharma. The company has 71 employees. Its chief executive, as recorded, is Chase Coffman. Elektrofi offers products and services including Hypercon Platform. Its focus areas include Life Sciences, Drug Delivery and Intradermal. Its legal entity is Elektrofi, Inc.,. Its competitors include Somalogic, Nautilus Biotechnology and Amunix; 3 of its 3 listed competitors have raised funding.
Company details
Elektrofi was founded in 2016 and is headquartered in Boston, United States. Operations focus on the biotechnology sector, where a digital platform is employed to advance the administration of biologic medicines. Proprietary Hypercon microparticle technology is integrated to formulate concentrated biologic drugs, allowing treatments to be delivered through straightforward subcutaneous injections rather than traditional methods.
- Headquarters Boston, United States
- Employees 71
- Founders Chase Coffman, Jason Norris
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website elektrofi.com
- Social LinkedIn X
- Acquired by Halozyme (Oct 2025)
- Legal Name Elektrofi, Inc.,
Products & Services of Elektrofi
Elektrofi offers a comprehensive portfolio of products and services, including Hypercon Platform.
Enables hyper-concentrated microparticle delivery of biologic therapies subcutaneously
Funding Insights of Elektrofi
Elektrofi has successfully raised a total of $152.25M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $112.25 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $152.25M
- Total Rounds 4
- Last Round Series C — $112.25M
- First Round $224,923
(Jul 2017)
- Investors Count 11
All 4 funding rounds of Elektrofi with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2024 | $112.25M | Series C | – | Novo Holdings, RA Capital Management | |
| Jun 2022 | $40M | Series B | – | Marshall Wace, BVF Partners | |
| Sep 2018 | $1.63M | Grant | – | – | |
| Jul 2017 | $224,923 | Grant | – | – |
12 investors in total: 12 institutional.
Investors in Elektrofi
Elektrofi has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Halozyme and Royalty Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Investments are made in marketed and late-stage biopharmaceutical companies. | 1996 | royaltypharma.com | New York, United States | |
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
Long-short equity strategies are managed through specialized hedge funds. | 1997 | mwam.com | London, United Kingdom | |
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Venture capital fund backed by the US Government | seedfund.nsf.gov | Alexandria, United States | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for Elektrofi
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Elektrofi
31 people are tracked at Elektrofi (15 in leadership, 16 in team); the tracked headcount is 71.
| Name | Role | Group |
|---|---|---|
Chase Coffman | Co-Founder & CEO | Leadership |
Jason Norris | Co-Founder & COO | Leadership |
Alex Stankiewicz | Associate Director, Business Development & Alliance Management | Leadership |
Victoria Sluzky | Chief Technology Officer | Leadership |
Ben Enerson | Senior Vice President, Legal & HR | Leadership |
Bernice Yeung | Executive Director, Analytical Development | Leadership |
Jason M. | Senior Vice President, Head Of Technical Operations | Leadership |
Alison Higgins | Director Quality (technical Quality Operations) | Leadership |
Joanne Tzouvalopoulos Beck | Chief Operating Officer | Leadership |
Jacob Martin | Associate Director Of Analytical Development, Biochemistry & Microbiology | Leadership |
Angela Hui | Vice President, Operations | Leadership |
Leo Takaoka | Director of IP and Patent Counsel | Leadership |
Chaitanya Sudrik | Director, Formulation Development | Leadership |
Greg DeFilippis | Chief Business Officer | Leadership |
Paul Brown | Head Of Drug Product Innovation | Leadership |
Ashley Wilson | Senior Scientist, Analytical Development (biochemistry) | Team |
Gabriel Lind | Senior Research Associate | Team |
Lisa Liu | Senior Engineer | Team |
Paul Herbert | SVP, Pharmaceutical Development | Team |
Sadiqua Shadbar | Senior Scientist II | Team |
11 more people are available in the full profile.
Complete people profiles for Elektrofi
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Elektrofi
4 dated milestones of Elektrofi across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Elektrofi is founded.
- Funding First funding round of $225K.
- Funding Latest funding round, Series C, of $112.3M.
- Exit Acquired by Halozyme.
Competitors of Elektrofi
Elektrofi has 3 listed competitors in our database, 3 of them funded. They include Somalogic, Nautilus Biotechnology and Amunix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| somalogic.com | 1999 | Boulder, United States | $663.99M | 319 | Protein-based assays are developed for life science research. | |
| nautilus.bio | 2016 | Seattle, United States | $103.26M | 134 | A proteomics platform is developed for analyzing the human proteome. | |
| amunix.com | 2006 | Mountain View, United States | $200.59M | 82 | Peptide-based therapeutics are developed for cancers and immune disorders. |
Detailed competitors of Elektrofi
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Elektrofi
The website of Elektrofi (elektrofi.com) receives about 4.3K visits a month.
- Monthly visits4.3K
▼ 16.7% vs previous month
Websites whose visitors overlap most with Elektrofi. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
alkalolcompany.com | alkalolcompany.com | 100% | #4,921,770 | – | |
sunradiopharma.com | sunradiopharma.com | 98% | #9,882,217 | – | |
| octagontherapeutics.com | 97% | 2K | #8,651,290 | View details | |
| servier.us | 96% | #2,050,491 | View details | ||
| aisapharma.com | 95% | 1.6K | #9,620,510 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Elektrofi
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Elektrofi (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Elektrofi
Complete news archive for Elektrofi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Elektrofi
Elektrofi was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Elektrofi is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Chase Coffman is the CEO of Elektrofi, as recorded in our data. They have also founded this company.
Elektrofi is a funded company, having raised a total of $152.25M across 4 funding rounds to date. The company's 1st funding round was a Grant of $224.92K, raised on Jul 2017.
Elektrofi has 71 employees.
Elektrofi was founded in 2016 and is headquartered in Boston, United States. Operations focus on the biotechnology sector, where a digital platform is employed to advance the administration of biologic medicines. Proprietary Hypercon microparticle technology is integrated to formulate concentrated biologic drugs, allowing treatments to be delivered through straightforward subcutaneous injections rather than traditional methods.
Elektrofi's top competitors include Somalogic, Nautilus Biotechnology and Amunix.
Elektrofi offers Hypercon Platform.
Elektrofi has 12 investors. Key investors include Lilly, Halozyme, Royalty Pharma, TPG, and Marshall Wace.
Elektrofi operates through Elektrofi, Inc.,.
Yes. Elektrofi was acquired by Halozyme in October 2025.